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Abstract
Background: Resistin, a member of adipokine family, is known to be involved in the modulation of immune responses 
including inflammatory activity. Interestingly, resistin is secreted by adipocytes in mice and rats whereas it is secreted 
by leukocytes in humans. However, the mechanism behind the effect of resistin on the expansion of regulatory T cells 
(Tregs) remains poorly understood. Therefore, we examined regulatory effect of resistin on the induction and cellular 
modification of Tregs.
Results: Both protein and mRNA expression of FoxP3, a representative marker of Tregs, increased in a dose-dependent 
manner when peripheral blood mononuclear cells were treated with resistin. At the same time, resistin had no direct 
effect on the induction of FoxP3 in CD4+ T cells, suggesting an indirect role through other cells type(s). Since DCs are an 
important player in the differentiation of T cells, we focused on the role of DCs in the modulation of Tregs by resistin. 
Resistin suppressed the expression of interferon regulatory factor (IRF)-1 and its target cytokines, IL-6, IL-23p19 and IL-
12p40, in DCs. Furthermore, FoxP3 expression is increased in CD4+ T cells when co-cultured with DCs and 
concomitantly treated with resistin.
Conclusion: Our results suggest that resistin induces expansion of functional Tregs only when co-cultured with DCs.
Background
Resistin, a novel adipocyte-secreted hormone, has gained
attention for its involvement in insulin resistance in obe-
sity and diabetes mellitus [1]. In murine animals, resistin
is secreted from mature white adipocytes and decreases
insulin sensitivity, whereas in humans it is mainly
secreted from immune cells such as macrophages and
monocytes and organs such as the spleen and bone mar-
row [2]. Recently, several groups have reported a close
relationship between resistin and inflammation. Resistin
increases the production of pro-inflammatory cytokines
tumor necrosis factor-α (TNF-α) and interleukin (IL)-12,
both of which are important for T cell development,
through the regulation of NF-κB signaling pathway in
human macrophages [3]. In the clinical setting, high lev-
els of resistin expression are present in patients with
rheumatoid arthritis [3].
Forkhead box P3 (FoxP3), a key regulator of the devel-
opment of regulatory T cells (Tregs, CD4+ CD25+ FoxP3+
T cells), is a hallmark of Tregs [4], which exhibit a sup-
pressive response to the effector function of CD4+ T cells
[5]. Two types of Tregs have been reported: natural Tregs
(nTregs), which naturally occur in the thymus, and induc-
ible Tregs (iTregs), which can be induced from naïve T
cells. The iTregs exhibit less suppressive function to
effector T cell responses than nTregs [6]. Interleukin (IL)-
2, transforming growth factor-β (TGF-β) and ligands for
the activation of T cell receptors (i.e., anti-CD2, -CD3
and -CD28) have been reported as important factors in
the induction of Tregs from naïve T cells [7].
Dendritic cells (DCs) play a vital role in the modulation
and activation of T cells, not only for the delivery and
presentation of antigenic determinant(s) to T cells, but
also in the induction of differentiation of naïve T cells
into T cells subtypes via cytokine secretion and/or cell-
to-cell contact [8]. Recently, several studies have reported
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that DCs are closely involved in the differentiation of
Tregs. For example, DCs either secreting TGF-β or in the
presence of TGF-β induce differentiation of
CD4+CD25+FoxP3+ T regs [9]. Interferon regulatory fac-
tor-1 (IRF-1)-/- DCs enhance the suppressive ability of
Tregs and cause tolerogenic features via induction of
Tregs due to the fact that the IRF-1-/- DCs secrete more
IL-10 and TGF-β but less IL-6, IL-12p40 and IFN-γ than
wild type DCs [10].
We previously reported that resistin impairs the ability
of human monocyte-derived DCs to uptake antigens and
produce cytokines (IL-12p40, IL-6 and TNF-α). These
impaired DCs negatively regulate T cell responses such as
proliferation of and differentiation into Th1 cells [11]. In
the current study, we further examine the ability of DCs
treated with resistin to induce expansion of Tregs.
Methods
Reagents
Human recombinant resistin, endotoxin level less than
0.1 ng/μg, was purchased from Peprotech (Rocky Hill,
NJ). To provide the effects of irrelevant control, we trans-
formed recombinant resistin to heat-inactivated resistin
through incubation with 100°C for 10 min. RPMI-1640
Glutamax medium, fetal bovine serum (FBS) and antibi-
otics (100 U/ml penicillin and 100 μg/ml streptomycin)
were purchased from Invitrogen (Grand Island, NY).
Preparation of human monocyte-derived DCs and CD4+ T 
cells
PBMCs were isolated by density gradient centrifugation
(420 × g for 25 min without brake) using Ficoll-Paque
Plus (Amersham Bioscience, Buckinghamshire, UK). All
experiments involving human blood were approved by
the Institutional Review Board of Seoul National Univer-
sity (IRB no. 0705/001-002). CD14+ monocytes or CD4+
T cells (purity > 95%) were isolated from PBMCs using
magnetic bead-based positive selection with a kit (BD
Biosciences, San Diego, CA). CD14+ monocytes were sus-
pended in complete media consisting of RPMI-1640 Glu-
tamax medium supplemented with 10% FBS and 1 mM
sodium pyruvate, 100 U/ml penicillin and 100 μg/ml
streptomycin. To generate immature DCs, isolated
CD14+ monocytes were cultured with 500 U/ml of hrIL-4
and 800 U/ml of hrGM-CSF (both from R & D Systems,
Minneapolis, MN) for 6 days with a change of media
every 3 days.
RNA isolation and reverse transcriptase-polymerase chain 
reaction (RT-PCR)
Cells were lysed with 1 ml of Trizol (Invitrogen) and 200
μl of chloroform was added. The tubes were shaken gen-
tly and incubated for 5 min at room temperature. The
tubes were centrifuged at 12,000 × g for 17 min and the
aqueous phase containing RNA was transferred into a
new tube. After transfer, 0.5 ml of isopropanol was added
to the RNA solution, mixed by gentle inversion, and then
incubated for 10 min at room temperature. The sus-
pended RNA was precipitated by centrifugation at 12,000
× g for 12 min. The supernatant was discarded and the
RNA pellet was washed with 75% ethanol followed by
centrifugation at 7500 × g for 7 min. The supernatant was
discarded and the RNA pellet was re-suspended in nucle-
ase-free water.
Isolated total RNA was reverse-transcribed into cDNA
with oligo-dT primers (Promega, San Luis Obispo, CA).
The cDNA was amplified by PCR in a total volume of 10
μl containing 0.5 units of Taq polymerase and two pico-
moles of specific primers for human FoxP3, TGF-β, IRF-
1, IL-12p40, IL-6, IL-10, CTLA-4 or β-actin (Table 1).
PCR was performed in a thermal cycler (Bio-Rad Labora-
tories, Hercules, CA) with pre-denaturation at 94°C for 5
min, followed by 28 cycles of denaturation at 94°C for 30
sec, annealing at the appropriate annealing temperature
(Table 1) for 30 sec and extension at 72°C for 1 min, and
finished with an additional elongation step for 7 min at
72°C. Amplified PCR products were separated by electro-
phoresis using a 2% agarose gel containing 1 μg/ml ethid-
ium bromide. To quantitate the expression of each
mRNA, the ratio of each mRNA to β-actin was measured
using Multi-gauge software (Fujifilm, Tokyo, Japan).
IRF-1 detection by Western blot analysis
5 × 105 cells of DCs incubated with 500 ng/ml of resistin
for different time periods (0, 1, 6, 12 and 24 hrs) in 24-
well plate (Nalgene Nunc International, Rochester, NY)
were washed with cold phosphate buffered saline (PBS)
and then lysed in RIPA lysis buffer containing 150 mM
NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM
Tris pH7.4, protease inhibitor cocktail (Roche, Man-
nheim, Germany), 2 mM NaF, 0.1 mM sodium orthovan-
adate and 2 mM glycerol phosphate. After centrifugation
at 28,000 × g for 7 min at 4°C, the supernatant was trans-
ferred to a new tube and the concentration of protein was
determined by Bradford assay (Bio-Rad Laboratories)
with bovine serum albumin (BSA) as a standard. Twenty-
five micrograms of proteins were separated by 12% SDS-
polyacrylamide gel electrophoresis and transferred to a
polyvinylidene difluoride membrane (Amersham Biosci-
ence). The membrane was blocked with 5% non-fat milk
containing Tris-buffered saline Tween-20 (TBST; 0.1 M
Tris, 0.9% NaCl, and 0.1% Tween 20) overnight at 4°C.
After washing three times with TBST, the membrane was
incubated with rabbit anti-human IRF-1 antibody (Santa
Cruz Biotechnology, Inc) for 3 hrs at room temperature
and washed with TBST three times. Protein bands were
detected using mouse anti-rabbit IgG conjugated with
horseradish peroxidase (Chemicon, Temecula, CA) andSon et al. BMC Immunology 2010, 11:33
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Table 1: The primers used in the present study for RT-PCR
Primer Sequences AT* Product size NCBI numbers
(°C) (bp)
FoxP3 forward: 5'-AGT TCC TCC ACA ACA TGG AC-3' 57 219 NM_014009
reverse: 5'-CAA AGC ACT TGT GCA GAC TC-3'
TGF-β forward: 5'-AAA GAC TTT TCC CCA GAC CT -3' 58 155 NM_000660
reverse: 5'-AAG GTG GGT GGT CTT GAA TA -3'
IRF-1 forward: 5'-GTG AAA GAC CAG AGC AGG-3' 57 400 NM_002198
reverse: 5'-CTG TTG TAG CTT CAG AGG-3'
IL-12p40 forward: 5'- GGA CCA GAG CAG TGA GGT CTT-3' 57 209 AF180563
reverse: 5'-CTC CTT GTT GTC CCC TCT GA-3'
IL-6 forward: 5'- TAG CCG CCC CAC ACA GAC AG-3' 61 408 NM_000600
reverse: 5'-GGC TGG CAT TTG TGG TTG GG-3'
IL-10 forward: 5'- AGA AAG GCA TCT ACA AAG CCA-3' 58 239 NM_000572
reverse: 5'-TGG GGG TTG AGG TAT CAG AG-3'
CTLA-4 forward: 5'- AGT TTT GTG GAG GAG CTC AG-3' 57 247 AF414120
reverse: 5'-CTC CTG GAG TAA GCC ATT GT-3'
β-actin forward: 5'- GGA CTT CGA GCA AGA GAT GG-3' 55 234 NM_001101
reverse: 5'-AGC ACT GTG TTG GCG TAC AG-3'
*AT, annealing temperature
developed by the enhanced chemiluminescence system
(GE Healthcare, Buckinghamshire, UK).
TGF-β detection by enzyme-linked immunosorbent assay 
(ELISA)
CD4+ T cells and DCs (2×105 cells each) were co-cultured
with or without 0.5 μg/ml of resistin for 4 days. Anti-
human CD2 and CD3 antibodies (0.1 μg/ml each) (Milte-
nyi Biotec, Auburn, CA) were then added and the cul-
tures were incubated for 3 more days. The concentration
of human TGF-β in the supernatant was measured using
an ELISA DuoSet kit (R & D Systems). Briefly, TGF-β
capture antibody was coated on each well of a 96-well
plate (Nalgene Nunc International) and incubated over-
night at 4°C. The wells were blocked with blocking buffer
(0.1% BSA in PBS) for 1 hr. After oxidation-reduction of
the supernatant to activate TGF-β, the supernatants from
the culture or standard samples were added and incu-
bated for 2 hrs at room temperature. Next, detection anti-
body conjugated with biotin was added to each well and
incubated for 2 hrs at room temperature. The plates were
washed three times with washing buffer (0.05% Tween 20
i n  P B S )  b e t w e e n  e a c h  s t e p .  T h e  s p e c i f i c  r e a c t i o n  w a s
detected using streptavidin-HRP followed by TMB in the
substrate buffer (Sigma-Aldrich Co., Saint Louis, MO).
The reaction was stopped with 2NH2SO4 and the amount
of TGF-β was measured by microplate reader (Molecular
Devices, Sunnyvale, CA).
Flow cytometric analysis
Cells cultured under different conditions were harvested
and washed three times with cold PBS. The cells were
stained with the desired combination of anti-human
CD25-APC and FoxP3-PE antibodies (BD biosciences)
for 20 min at 4°C in the dark. The cells were washed and
changes in marker expression were measured using a
FACSCalibur with Cell-Quest software (BD Biosciences).
All flow cytometric data were analyzed with FlowJo soft-
ware (Tree Star, San Carlos, CA).
To evaluate the effect of TGF-β on the induction of
Tregs, CD4+  T cells co-cultured with DCs were pre-
treated for 1 hr TGF-β receptor I inhibitor (Calbiochem,
San Diego, CA). After pre-treatment, the cells were incu-
bated with or without resistin (0.5 μg/ml) for 4 days and
then anti-human CD2 and CD3 antibodies were added
and the cultures were incubated for an additional 3 days.
After staining the cells with anti-human CD25-APC and
FoxP3-PE antibodies, CD25+ FoxP3+ Tregs were detected
using flow cytometry as described above.
Suppression activity of Tregs against CD4+ CD25- T cells
CD4+ T cells and DCs were co-cultured with or without
0.5 μg/ml of resistin for 4 days and then anti-human CD2
and CD3 antibodies (Miltenyi Biotec) were added and the
cultures were incubated for 3 more days. After washing
with cold PBS, the cells were stained with anti-human
CD25-APC antibody for 20 min at 4°C in the dark andSon et al. BMC Immunology 2010, 11:33
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then washed with cold PBS. CD25+ T (e.g., CD4+ CD25+ )
effector cells (purity > 97%) were isolated using anti-APC
particles (BD biosciences) together with IMag™, a mag-
netic bead-based positive selection kit (BD biosciences).
CD4+ CD25- T cells (purity > 95%) were isolated using a
regulatory T cell isolation kit (Miltenyi Biotec), labeled
with 2.5 μM of CFSE (Invitrogen) for 8 min in 37°C and
u s e d  a s  t a r g e t  c e l l s .  E f f e c t o r  c e l l s  ( 2 × 1 0 5 cells) and an
equal number of target cells were co-cultured with anti-
human CD2 and CD3 antibodies (Miltenyi Biotec) for an
additional 5 days in a 24-wells plate. The intensity of
CFSE in the target cells was measured using a FACSCali-
bur with CellQuest (BD Biosciences). All flow cytometric
data were analyzed by FlowJo software (Tree Star).
Statistical analysis
Comparative data were analyzed using Student's t-test
and considered statistically significant when the P value
was less than 0.05.
Results
Resistin induces expression of FoxP3 in PBMC, but not in 
CD4+ T cells
To examine whether resistin could modulate the induc-
tion of Tregs, we tested the expression level of FoxP3 in
PBMCs and CD4+ T cells. FoxP3 is one of the most repre-
sentative markers of Tregs, together with CTLA4, TGF-β
and IL-10 [6]. Since FoxP3 is expressed in T cells only,
PBMCs and CD4+ T cells were incubated with 0, 50, 100,
200 or 500 ng/ml of resistin for 6 hrs. The expression
level of FoxP3  w a s  t h e n  m e a s u r e d  b y  R T - P C R .  T h e
expression of FoxP3 increased significantly (P< 0.05) in a
dose-dependent manner in PBMCs treated with resistin
(figure 1A and 1C). Minimal, if any, change was found in
the expression of TGF-β (figure 1A). It is to note that the
expression level of FoxP3 and TGF-β was, unexpectedly,
not changed in CD4+ T cells treated with any concentra-
tion of resistin (figure 1B and 1C). These results suggest
that the resistin-induced expression of FoxP3 in Tregs is
mediated by indirect where CD4+ cells are not necessarily
required.
Resistin-treated DCs enhance the expansion of Tregs
The primary role of DCs is to interact with T cells and
trigger adaptive immune responses, but DCs are also
involved in the differentiation of Tregs [12]. Therefore, to
further examine whether resistin-treated DCs are
involved in the regulation of Tregs, CD4+ T cells and DCs
were co-cultured and concomitantly treated with resistin.
mRNA expression levels of TGF-β, CTLA-4 and FoxP3,
representative markers of Tregs, were subsequently mea-
sured. The expression of TGF-β, CTLA-4 and FoxP3 was
greater in cells treated with resistin than those without
resistin treatment (figure 2A). This finding was further
confirmed by changes of CD4+ CD25+ FoxP3+ Tregs using
f l o w  cy t o m e t ry .  A s  s h o w n  i n  f i g u r e  2 B  ( u p p e r  p a n e l ) ,
CD4+ CD25+ FoxP3+ cells were significantly (P  < 0.05)
higher in cells treated with resistin than those without
treatment (additional file 1). And, to confirm whether the
increased number of Tregs were induced from naïve
CD4+ T cells or expanded from Tregs, CD4+ CD25- naïve
T cells were co-cultured and concomitantly treated with
resistin. The result showed that CD25+ FoxP3+ Tregs were
expanded from Tregs but were merely induced from
CD4+ CD25- naïve T cells when co-cultured with resistin-
treated DCs (figure 2B bottom panel). Finally, CD4+
CD25+ T cells were isolated after co-culture of T cells and
DCs concomitantly treated with/without resistin in order
to examine their functional capacity to suppress the
activity of effector T cells. CD4+ CD25- T cells labeled
with CFSE were co-cultured with CD4+ CD25+ T cells
and stimulated with anti-human CD2 and CD3 antibod-
ies. When compared with a proliferation of CD4+ CD25-
naïve T cells only, the CD4+ CD25+ Tregs induced by DCs
treated with resistin suppressed the proliferation of CD4+
CD25-  naïve T cells similar to CD4+  CD25+  T cells
induced by DCs without resistin (figure 2C). These
results suggest that resistin modulates the functionality of
DCs to enhance the expansion of CD4+ CD25+ FoxP3+
Tregs.
The effects of resistin in DCs for expansion of Tregs
Next, we examined the change of IRF-1 and cytokines,
IL-12p40, IL-23p19, IL-6, IL-10 and TGF-β in relation to
the differentiation of T cells. IRF-1 both, at mRNA (figure
3A) and protein level (figure 3B) was suppressed in a
time- and dose-dependent manner when DCs were
treated with resistin.  Note that heat-inactivated resistin
was used. It has been previously shown that the expres-
sion of inflammatory cytokines, TNF-α, IFN-γ, IL-12p40
and IL-15, was significantly reduced while the expression
of tolerogenic cytokines, IL-10 and TGF-β, was increased
in DCs from IRF-/- mice [10]. IL-12, IL-23 and IL-6 are
known to be involved in the differentiation of naïve T
cells into Th1 and Th17 subtypes, respectively, while IL-
10 and TGF-β induce the differentiation of Tr1 and Th3
subtypes, respectively [13]. Accordingly, we further
examined the expression of IL-12p40, IL-23p19, IL-6, IL-
10  and  TGF-β  in DCs after resistin treatment. The
expression of IL-12p40, IL-23p19 and IL-6 decreased in
DCs treated with resistin, while no significant differences
were observed in the expression of IL-10 and TGF-β (fig-
ure 3C). And through the PI/annexin V, CD40, CD80,
CD86 and MHC class II staining, we confirmed that
resistin is involved in the process of neither apoptosis nor
maturation of DCs (data not shown). These results sug-
gest that resistin suppresses the expression of IL-12p40,Son et al. BMC Immunology 2010, 11:33
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IL-23p19 and IL-6 through the regulation of IRF-1 induc-
tion in DCs.
Tregs were induced by TGF-β secreted by themselves but 
not by DCs treated with resistin
To investigate whether TGF-β secreted from DCs is
involved in the induction of Tregs, CD4+ T cells were pre-
treated with TGF-β receptor inhibitor, co-cultured with
DCs, and concomitantly treated with resistin. Tregs were
induced when the cells were treated with resistin as
expected, but treatment with TGF-β receptor inhibitor
suppressed such induction (figure 4A). We also examined
the level of TGF-β in the culture supernatant. TGF-β
increased in CD4+ T cells when co-cultured with DCs and
treated with resistin (figure 4B). The expression of TGF-β
mRNA was not significantly different in DCs alone
treated with resistin (figure 4C). These results suggest
that TGF-β produced from CD4+ T cells co-cultured with
DCs together with resistin treatment, was the major
source to induce the differentiation of Tregs, rather than
TGF-β secreted from DCs.
Discussion
The major findings of this study are as follow: (i) Resistin
indirectly induced the expression of FoxP3 in PBMCs, (ii)
Resistin suppressed the expression of IRF-1, IL-6, IL-
12p40 and IL-23p19 in DCs, (iii) DCs treated with resis-
tin enhanced the expansion of CD4+ CD25+ FoxP3+ T
cells, (iv) TGF-β caused the expansion of Tregs and (v)
TGF-β was mainly produced from Tregs during the co-
culture of T cells and DCs together with resistin treat-
ment.
Resistin was originally described because of its promo-
tion of resistance against the insulin response [1] and adi-
pogenesis in fat tissue [14]. More recently, important
roles of resistin in the human immune response [15] and
inflammation, including induction of pro-inflammatory
cytokines, [2,3,16] have been reported. In the previous
s t u d y ,  w e  r e p o r t e d  t h e  i m m u n o m o d u l a t o r y  e f f e c t  o f
resistin on human DCs for the first time [11]. We have
demonstrated that resistin impairs not only the ability of
antigen-uptake and cytokine production in DCs, but also
the proliferation and differentiation of T cells. These
results suggest that the DCs treated with resistin may
negatively regulate the effector function of T cells. Our
findings are in agreement with those of Rutella et al., who
also reported that tolerogenic DCs, known to express
high amounts of IL-10 but not IL-12 in the immature
state, induce Tregs [17]. It is to note that Tregs are well
known for their role in suppressing a variety of T cell
responses. Tregs also regulate DCs and NK cells by sup-
pressing expression of the CCR5 ligand and IL-15Rα,
respectively [18]. Accordingly, we hypothesized that
resistin could be involved in the expansion of Tregs
through the regulation of DCs.
In order to clarify whether resistin could induce the
expansion of Tregs, we treated PBMCs and purified CD4+
T cells with resistin and analyzed the changes in FoxP3
expression. Resistin had no direct effect on the induction
of  FoxP3  mRNA expression in CD4+ T cells, but did
increase FoxP3  mRNA in PBMCs. This result suggests
that resistin may indirectly induce Tregs through the reg-
ulation of other cell types, most likely DCs. Tregs can be
induced by cell-to-cell contact, for instance, DCs and T
cells. DCs, producing TGF-β, IL-10 and indoleamine 2,3-
dioxygenase can induce the differentiation of Tregs in
vitro and in vivo [12]. Since immature DCs have a better
Figure 1 Expression of FoxP3 mRNA in PBMCs or CD4+ T cells 
treated with resistin. (A) PBMC and (B) CD4+ T cells isolated from hu-
man adult peripheral blood were treated with various concentrations 
of resistin (0, 50, 100, 200 or 500 ng/ml) for 6 hrs. For measurement of 
FoxP3 and TGF-β mRNA expression, RT-PCR was performed as de-
scribed in Materials and Methods. (C) The intensities of the FoxP3 were 
normalized to β-actin. Results are representative of three separate ex-
periments with similar results.Son et al. BMC Immunology 2010, 11:33
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Figure 2 The number of Tregs increased when co-cultured with DCs and concomitantly treated with resistin. CD4+ T cells or CD4+ CD25- T 
cells and DCs were co-cultured with 500 ng/ml of resistin for 4 days. The cells were then incubated with anti-human CD2 and CD3 antibodies for an 
additional 3 days. (A) At the end of the incubation period, total RNA was isolated and subjected to RT-PCR to measure mRNA expression of CTLA-4, 
FoxP3 and TGF-β. (B) After the staining of the cells with anti-human CD25-APC and -FoxP3-PE antibodies, CD25+FoxP3+ Tregs were analyzed by flow 
cytometry. (C) After the staining with anti-human CD25-APC antibody, CD25+ T cells were isolated using anti-APC magnetic beads. The isolated CD25+ 
T cells and CD4+ CD25- naïve T cells labeled with CFSE were co-cultured with DCs and stimulated with anti-human CD2 and CD3 antibodies for 5 days. 
Cell proliferation was measured by flow cytometry. The value in each panel indicates the percentage of CD25+ FoxP3+ Tregs.Son et al. BMC Immunology 2010, 11:33
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ability to induce Tregs than mature DCs [19], we exam-
ined changes in the expressin of DC maturation markers
(CD40, CD80, CD86 and HLA-DR) following resistin
treatment (data not shown). We found no evidence for
the involvement of resistin in the maturation of DCs,
implying that the induction of Tregs is independent of
DC maturation.
We further demonstrated that resistin suppressed the
expression of IRF-1 and cytokines such as IL-6, IL-12p40
and IL-23p19 in DCs, suggesting the possibility that resis-
tin-treated DCs are involved in the induction of Tregs.
Indeed, IL-6 enhances the conversion of Th17 cells to
Tregs when combined with TGF-β, whereas it inhibits
leukemia inhibitory factor (LIF), which is an essential fac-
tor for inducing FoxP3 expression in Tregs [20]. On the
other hand, IL-12 is known as one of the most important
cytokines for inducing differentiation of naïve T cells into
Th1 cells [21]. IL-23p19 is well known as the important
source to induce Th17 cells [13]. Therefore, these
decrease of effect cytokines support the enhancing
expansion of Tregs.
The down-regulation of IRF in our findings is sup-
ported by a previous study in IRF-1-/- mice, which have
h i g h  l e v e l s  o f  C D 4 +CD25+FoxP3+  Tregs, where the
expression of FoxP3 was negatively regulated by IRF-1
[22]. We found that the expression of FoxP3 and CTLA-4
increased in parallel with the suppressive effect of Tregs
when CD4+ T cells were co-cultured with DCs in the
presence of resistin.
It has been shown that suppressors of cytokine signal-
ing (SOCS) 3-deficient DCs, together with impaired pro-
duction of cytokines (IL-12, IFN-γ and IL-6) and co-
stimulatory molecules (CD40 and CD86), preferentially
induce the expansion of Tregs [23]. Our results also sug-
gest that resistin decreases the production of SOCS3 in
DCs (data not shown). Tregs can be induced by soluble
factors, including TGF-β, IL10 and IL-2. TGF-β, in par-
ticular, suppresses inflammatory activity and promotes
differentiation of Tregs [5]. Accordingly, we examined the
source of TGF-β that provoked the expansion of Tregs.
We found that major source of TGF-β required for the
induction of Tregs was CD4+ T cells co-cultured with
DCs in the presence of resistin, and not DCs themselves
treated with resistin. It is to note that the treatment with
TGF-β or supernatant from any culture condition afore-
mentioned had no impact on the expansion of Tregs (data
not shown). Therefore it is most likely that in addition to
TGF-β produced from co-culture of CD4+ T cells and
Figure 3 Resistin suppressed the expression of IRF-1 and cytokines in DCs. The expression of IRF-1, in both (A) mRNA and (B) protein was deter-
mined in DCs treated with 500 ng/ml of resistin for the indicated time periods (upper panel in A and B) and treated with indicated amount for 24 hrs 
(bottom panel in A and B). The heat-inactivated resistin was used as a control. (C) The expression of IL-12p40, IL-23p19, IL-6, TGF-β and IL-10 was mea-
sured by RT-PCR in DCs treated with 500 ng/ml of resistin for 12 hrs. The graphs show the intensity of each cytokine normalized to β-actin. Results are 
representative of three separate experiments with similar result.Son et al. BMC Immunology 2010, 11:33
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Figure 4 TGF-β secreted by CD4+ CD25+ FoxP3+ Tregs, but not by DCs, induces the expansion of Tregs. CD4+ T cells were pre-treated with in-
hibitor for TGF-β receptor for 1 hr and co-cultured with DCs, followed by resistin treatment for 4 days. Anti-human CD2 and CD3 antibodies were then 
added to the cells for an additional 3 days. (A) CD25+ FoxP3+ Tregs were measured by flow cytometry. (B) TGF-β production in the supernatant was 
measured by ELISA. (C) DCs were treated with various concentrations (0, 50, 100, 200 and 500 ng/ml) of resistin for 6 hrs and then TGF-β mRNA expres-
sion was measured by RT-PCR. * P< 0.05. The value in each panel indicates the percentage of CD25+ FoxP3+ Tregs. The results represent the mean ± 
standard deviation from three separate experiments.Son et al. BMC Immunology 2010, 11:33
http://www.biomedcentral.com/1471-2172/11/33
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DCs in the presence of resistin, cell to-cell contact is crit-
ically required for the induction of Tregs.
Conclusions
We have shown that resistin induces the expansion of
regulatory T cells through regulating the expression of
IRF-1 and its target cytokines, IL-6, IL-23p19 and IL-
12p40 in human monocyte-derived dendritic cells.
Additional material
Abbreviations
BSA: bovine serum albumin; CFSE: carboxyfluorescein succinimidyl ester; CTLA:
cytotoxic T-lymphocyte antigen; DCs: dendritic cells; FBS: fetal bovine serum;
FoxP3: forkhead box P3; GM-CSF: granulocyte macrophage colony-stimulating
factor; HRP: horseradish peroxidase; IL: interleukin; IRF: interferon regulatory
factor; PBMC: peripheral blood mononuclear cells; PBS: phosphate buffered
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